Clinical Scorecard: Gene Therapies for Inherited Retinal Diseases
At a Glance
| Category | Detail |
|---|---|
| Condition | Inherited Retinal Diseases (IRD) |
| Key Mechanisms | Augmentation, RNA editing, and gene-agnostic approaches |
| Target Population | Patients with retinitis pigmentosa (RP), Stargardt disease, Leber congenital amaurosis (LCA), and X-linked retinoschisis (XLRS) |
| Care Setting | Ophthalmology clinics and clinical trials |
Key Highlights
- First retinal gene therapy, voretigene neparvovec (Luxturna), approved in 2017.
- Genetic testing is standard care for monogenetic IRD.
- Bota-vec shows promise in treating XLRP with manageable safety profile.
- Laru-zova demonstrates potential in restoring function in XLRP.
- ACDN-01 is the first RNA exon editor in clinical development for Stargardt disease.
Guideline-Based Recommendations
Diagnosis
- Genetic testing for monogenetic IRD is recommended.
Management
- Consider gene therapy options like bota-vec and laru-zova for XLRP.
Monitoring & Follow-up
- Monitor for treatment-emergent adverse events (TEAEs) post-gene therapy.
Risks
- 100% of participants in bota-vec trials experienced at least 1 TEAE.
Patient & Prescribing Data
Males with XLRP, typically affected by RPGR mutations.
Laru-zova and ACDN-01 show promise in improving visual function and safety.
Clinical Best Practices
- Stay updated on advancements in retinal genetics and gene therapy.
- Evaluate safety and efficacy in clinical trials before prescribing.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
